Fulton Breakefield Broenniman LLC Sells 9,561 Shares of Johnson & Johnson (NYSE:JNJ)

Fulton Breakefield Broenniman LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 31.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,284 shares of the company's stock after selling 9,561 shares during the quarter. Fulton Breakefield Broenniman LLC's holdings in Johnson & Johnson were worth $3,530,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the fourth quarter valued at $29,000. Conquis Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson in the fourth quarter valued at $36,000. Finally, Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.5%

JNJ opened at $156.87 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm's fifty day moving average is $153.75 and its 200 day moving average is $154.55. The stock has a market cap of $377.44 billion, a price-to-earnings ratio of 17.45, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Barclays dropped their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Finally, Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $171.00.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.